175 related articles for article (PubMed ID: 36798126)
1. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.
Wan S; Zhao E; Weissinger D; Krantz BA; Werba G; Freeman D; Khanna LG; Siolas D; Oberstein PE; Chattopadhyay PK; Simeone DM; Welling TH
Front Immunol; 2023; 14():1067352. PubMed ID: 36798126
[TBL] [Abstract][Full Text] [Related]
2. Role of genetic testing in hepatic, pancreatic, and biliary cancers.
Hewitt DB; Aziz H; Brown ZJ; Pawlik TM
Surg Oncol; 2022 Sep; 44():101844. PubMed ID: 36116416
[TBL] [Abstract][Full Text] [Related]
3. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
4. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
Barsch M; Salié H; Schlaak AE; Zhang Z; Hess M; Mayer LS; Tauber C; Otto-Mora P; Ohtani T; Nilsson T; Wischer L; Winkler F; Manne S; Rech A; Schmitt-Graeff A; Bronsert P; Hofmann M; Neumann-Haefelin C; Boettler T; Fichtner-Feigl S; van Boemmel F; Berg T; Rimassa L; Di Tommaso L; Saeed A; D'Alessio A; Pinato DJ; Bettinger D; Binder H; John Wherry E; Schultheiss M; Thimme R; Bengsch B
J Hepatol; 2022 Aug; 77(2):397-409. PubMed ID: 35367533
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of tissue-resident CD8
Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
[TBL] [Abstract][Full Text] [Related]
6. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
7. Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies.
Gorji L; Brown ZJ; Pawlik TM
Surg Oncol; 2024 Feb; 52():102031. PubMed ID: 38128340
[TBL] [Abstract][Full Text] [Related]
8. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
[TBL] [Abstract][Full Text] [Related]
9. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X
Front Immunol; 2023; 14():1112672. PubMed ID: 36993960
[TBL] [Abstract][Full Text] [Related]
11. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff SM; Shannon AH; Pawlik TM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
[TBL] [Abstract][Full Text] [Related]
12. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
13. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy for pancreatic cancer: challenges and future considerations.
Gössling GCL; Zhen DB; Pillarisetty VG; Chiorean EG
Expert Rev Clin Immunol; 2022 Nov; 18(11):1173-1186. PubMed ID: 36045547
[TBL] [Abstract][Full Text] [Related]
15. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.
Rakké YS; Buschow SI; IJzermans JNM; Sprengers D
Front Immunol; 2024; 15():1357333. PubMed ID: 38440738
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Chen LX; Zou SJ; Li D; Zhou JY; Cheng ZT; Zhao J; Zhu YL; Kuang D; Zhu XH
World J Gastroenterol; 2020 Dec; 26(48):7664-7678. PubMed ID: 33505143
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Biliary Tract Cancers: Where Are We?
Kalyan A; Khosla H; Kim RD
Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
[TBL] [Abstract][Full Text] [Related]
19. Promise and pitfalls of immune checkpoint inhibitors in hepato-pancreato-biliary malignancies.
McLoughlin KC; Brown ZJ; Shukla Y; Shukla V
Discov Med; 2018 Sep; 26(142):85-92. PubMed ID: 30399326
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
